Cet anticorps anti-BRCA1 Polyclonal Lapin (ABIN7224456) détecte spécifiquement BRCA1 dans WB, IHC, ELISA et IF.
L’anticorps est réactif avec des échantillons de Humain, Rat et Souris.
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-2000,IHC 1:100-1:300,ELISA 1:10000,IF 1:50-200
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C
Stockage commentaire
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Date de péremption
12 months
Antigène
BRCA1
(Breast Cancer 1 (BRCA1))
Autre désignation
BRCA1
Sujet
BRCA1, RNF53, Breast cancer type 1 susceptibility protein, RING finger protein 53BRCA1 (BRCA1, DNA repair associated) encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in BRCA1 are responsible for approximately 40 % of inherited breast cancers and more than 80 % of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for BRCA1, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified.